GlassScriptPhysician profile
Mark Dean Christensen
NPI 1588944516
$6,063.20
in general payments reported to CMS, 2019-2025
58 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $350 · 2021: $728 · 2022: $756 · 2023: $1,089 · 2024: $1,316 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,737.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,052.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $700.90 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $641.04 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $431.88 | 2020-2025 | |
| Glaxosmithkline, LLC. | $291.22 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $259.87 | 2021-2025 | Zepbound, Mounjaro, Kisunla |
| Amgen INC. | $256.06 | 2019-2025 | Otezla, Repatha, Evenity |
| Idorsia Pharmaceuticals US INC | $194.74 | 2022-2024 | Quviviq |
| Gilead Sciences, INC. | $159.00 | 2024-2025 | |
| Horizon Therapeutics Plc | $144.60 | 2019-2023 | Krystexxa |
| Lucid Diagnostics INC. | $104.85 | 2021-2024 | |
| Exact Sciences Corporation | $102.32 | 2023-2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $100.01 | 2021-2024 | Nuzyra |
| Genentech USA, INC. | $95.30 | 2019-2022 | |
| Boston Scientific Corporation | $86.41 | 2023-2025 | General - Therapies, Wavewriter Alpha Prime 16 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.